Immix Biopharma's NXC-201 Gets RMAT & ODD Designations for AL Amyloidosis
Immix Biopharma, Inc. (IMMX) has received significant regulatory recognition for its lead candidate, NXC-201. The US FDA and EMA have granted it Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug Designation (ODD) respectively, marking a crucial milestone in its development.
NXC-201 is a BCMA-targeted CAR-T cell therapy, designed to treat relapsed/refractory AL Amyloidosis. It stands out with its 'digital filter' mechanism, which reduces non-specific activation. Currently, it's being evaluated in a U.S. multi-center study, NEXICART-2, with a registrational design that met its primary endpoint at interim results presented at ASCO 2025.
Immix Biopharma, a clinical-stage biopharmaceutical company, will present and host investor meetings at the 37th Annual Piper Sandler Healthcare Conference. The event will take place at the Lotte New York Palace Hotel in New York, NY from December 2-4, 2025. While the specific representative from Immix Biopharma is not named, Dr. Nancy T. Chang, a key executive figure and board member since September 2025, is expected to be involved.
With these designations, Immix Biopharma's NXC-201 is poised for further advancement in treating AL Amyloidosis. The upcoming conference provides an opportunity for investors to learn more about the company's progress. For more information about AL Amyloidosis, visit www.BeProactiveInAL.com.
